HRT and breast cancer

Impact on population risk and incidence

Nathan J. Coombs, Richard Taylor, Nicholas Wilcken, John Boyages*

*Corresponding author for this work

Research output: Contribution to journalArticle

24 Citations (Scopus)


This study has calculated the potential impact of hormone replacement therapy (HRT) on breast cancer incidence in Australia and has estimated how changes in prescribing HRT to women could affect this risk. The effects of HRT on breast cancer incidence was estimated using the attributable fraction technique with prevalence data derived from the 2001 Australian Health Survey and published rates of breast cancer relative risks from HRT use. In Australia, 12% of adult women were current HRT users and in 2001, 11 783 breast cancers were reported. Of these, 1066 (9%) were potentially attributable to HRT. Restricting HRT use to women aged less than 65 years, ceasing HRT prescribing after 10 years or limiting combined oestrogen and progesterone HRT to five years (but otherwise keeping prescription levels to 2001 levels) may reduce the annual breast cancer caseload by 280 (2.4%), 555 (4.7%) or 674 (5.7%), respectively. In conclusion, this study has demonstrated that when HRT prevalence is relatively high, the effect on breast cancer incidence in the population will be significant. A small modification in HRT prescribing practices may impact breast cancer incidence in Australia with associated financial and health care provision implications.

Original languageEnglish
Pages (from-to)1775-1781
Number of pages7
JournalEuropean Journal of Cancer
Issue number12
Publication statusPublished - Aug 2005
Externally publishedYes


  • Breast cancer
  • Hormone replacement therapy
  • Oestrogen
  • Progesterone

Fingerprint Dive into the research topics of 'HRT and breast cancer: Impact on population risk and incidence'. Together they form a unique fingerprint.

Cite this